DeepCure to Present 'Laparoscopic RDN Clinical Results' at TCT 2024... "Proving Technology and Innovation"
DeepCure, developing the world's first laparoscopic renal denervation (RDN) medical device 'HyperQure' for the treatment of resistant hypertension, has disclosed clinical results. HyperQure is a medical device that treats resistant hypertension by laparoscopically blocking the sympathetic nerves around the renal artery.
On the 29th, DeepCure announced its participation in 'TCT 2024 (Transcatheter Cardiovascular Therapeutics)' held in Washington D.C., USA.
TCT is the world's most prestigious conference in the field of cardiovascular intervention. Every year, more than 10,000 cardiologists from 100 countries around the world gather to share new treatment methods and clinical progress in cardiovascular intervention. The event is being held over four days starting from the 27th of this month.
At this conference, Changwook Jeong, founder of DeepCure and professor at Seoul National University Hospital, along with researchers from CBSET (Center for Biomedical Science and Engineering Technology), a Good Laboratory Practice (GLP) certified institution that conducted the large animal preclinical studies for DeepCure's FDA submission, attended and presented.
Professor Changwook Jeong revealed the domestic clinical results of HyperQure, which have been ongoing since January this year. The company has successfully completed clinical surgeries using HyperQure on six hypertensive patients so far and plans to recruit an additional four clinical patients within this year.
Dr. Abraham Rami Tzafriri of CBSET presented on the "12-Week Safety and Efficacy of New Vascular Bilateral Renal Denitrification Device in Nominal-Dose Pig Model." The research team demonstrated the safety of HyperQure in animal models, which led to obtaining FDA Investigational Device Exemption (IDE) approval for clinical trials.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
A company representative stated, "By disclosing the clinical results of HyperQure at TCT 2024, we have globally showcased DeepCure's advanced technology and innovation," adding, "Based on the positive clinical outcomes, we plan to actively proceed with global clinical trials starting this November."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
